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Abstract
The available results from breast cancer chemoprevention trials are reviewed. Four trials
using tamoxifen have been performed, of which three have reported efficacy results. A fifth
trial using raloxifene has also been reported. The largest tamoxifen trial showed
approximately 50% reduction in breast cancer incidence in the short term, but the two
smaller trials did not find any reduction. Greater agreement exists for side effects; incidences
of thromboembolic disease and endometrial cancers are raised approximately threefold
when tamoxifen is used for 5 years. The possible reasons for the discrepancy in breast
cancer reduction are explored. A review of trial parameters does not clearly explain this
difference, and a meta-analysis indicates that all results are compatible with a 40% reduction
in short-term incidence. Several important questions remain regarding the clinical
implications of this result, including the effect on mortality, the appropriate risk groups for
chemoprevention and the long-term effects on incidence. Continued follow up of these trials
is crucial for resolving these issues.
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Introduction
Following the observation that tamoxifen reduced the inci-
dence of contralateral breast cancer when used in the adju-
vant setting, it was suggested that prevention of breast
cancer in high-risk women might also be possible with this
drug [1•,2•]. A pilot study was initiated under the auspices
of the United Kingdom Coordinating Committee for Cancer
Research at the Royal Marsden Hospital (RMH). As a result
of the favourable compliance data and lack of unexpected
toxicities in the RMH trial, the United Kingdom Coordinating
Committee for Cancer Research launched its main trial, the
International Breast Cancer Intervention Study (IBIS) in
1992.Subjects were first enrolled in Australia, because the
UK Medical Research Council were concerned about
hepatic toxicity of tamoxifen in some strains of rats and their
concerns delayed the onset of the study in the UK until
November 1993. A similar trial was initiated in the USA in
1992 under the auspices of the National Surgical Adjuvant
Breast Project (NSABP) [3•]. All trials were placebo-con-
trolled studies of 5 years of tamoxifen administration.
Three studies have reported early results on breast cancer
reduction. In the largest study, the NSABP Prevention 1
trial [3•], an almost 50% reduction in new tumours was
found. This result is very similar to that which was
expected from the adjuvant studies [4•], and led to thehttp://breast-cancer-research.com/content/2/4/258
early stopping, unblinding and curtailment of the American
trial. However, the preliminary results of the RMH trial [5•]
and the Italian trial [6•] did not indicate any reduction in
breast cancer incidence. These trials remain blinded at the
individual level and further follow up is continuing.
The present review examines the differences between these
trials, and assesses factors that might explain the differ-
ences in results. The IBIS trial is not scheduled to complete
recruitment until the end of 2000, and results on the reduc-
tion of breast cancer incidence are not available. However,
some demographic data are available from this trial, and
thus we can make some comparisons between it and the
three other tamoxifen prevention trials [3•,5•,6•]. A fifth trial
(Multiple Outcomes of Raloxifene Evaluation; MORE),
designed primarily to look at the value of 3 years of use of
the new selective oestrogen receptor modulator raloxifene
in preventing osteoporosis, has also recently reported on
breast cancer prevention [7•], and is also reviewed.
Demography
The entry criteria and basic characteristics of the five trials
are summarized in Tables 1 and 2. The number of subjects
entered into the NSABP trial [3•] is about the same as that
recruited into all of the IBIS, RMH [5•], Italian [6•] and
MORE [7•] trials combined. Because the NSABP trial
recruited quickly, there is already a median follow up of 55
months, compared with 30 months for the Italian study
and (currently) 30 months for IBIS. The smaller RMH study
has the longest median follow up (70 months).
The age ranges for entry were similar among the tamoxifen
trials, although a few women aged below 35 years were
entered into the RMH trial and a few who were aged over
70 years were entered into the NSABP trial. The median
age of entry was lower for the RMH and IBIS trials, and
more women were below the age of 50 years at entry. The
MORE trial entered only postmenopausal women under
the age of 80 and had a much older median age at entry.
The differences in age at entry are related to different entry
criteria for the five trials. The RMH and IBIS trials entered
mainly subjects with a family history of breast cancer (96
and 91%, respectively, had at least one first-degree rela-
tive with breast cancer). Indeed, in the RMH trial 36% of
patients were at risk sufficient to be potential carriers of
BRCA1 or BRCA2 mutations. In IBIS 20% of subjects
had two or more first-degree relatives with breast cancer
and the NSABP trial had 19%.
Because of concerns about tamoxifen-associated endo-
metrial cancer, the Italian trial admitted subjects only if
they had had a hysterectomy. Approximately half of the
women had also had an oophorectomy, some at a rela-
tively young age, so that many of the women entered into
this trial were at a lower than average risk for breast
cancer. The entry criteria for NSABP were calculated
according to the Gail model, which takes into account
family history (but not the age of the affected relative),
number of breast biopsies and hormonal risk factors. All
women aged 60 years or more were eligible and women
less than 60 had to have a 5-year risk of breast cancer
equivalent to that in a woman of 60 years. The entry crite-
ria for the IBIS trial are based on family history, benign
breast disease and nulliparity. A range of options for entry
was used to approximate a twofold risk compared to the
normal populkation for age in the range 45–70 years, a
fourfold risk for age in the range 40–44 years, and a 10-
fold risk for age in the range 35–39 years. Details were
provided by Cuzick [8]. Although pathological and
endocrine risk factors were allowed, in practice the large
majority of subjects were entered because of a history of a
young close relative with breast cancer. This was also true
of the RMH trial, but was less true for the NSABP study, in
which hormonal risk factors and breast biopsies were
more important entry criteria.
The MORE trial was designed to examine osteoporosis
primarily, and no risk factors for breast cancer were
required for entry. Raloxifene was given daily at two doses
(60 and 120mg), and these groups were combined for
analysis, so there were about twice as many patients in
the treated group (5129 versus 2576).
Compliance
Compliance is crucial for maintaining power in prevention
studies. Table 3 shows that this was remarkably good for
all studies, and was around 70–75% for tamoxifen,
although comparisons between trials are not valid because
of the different ways of presenting compliance data (crude
percentages, actuarial curves, percentage of prescribed
medication taken). Effective sample size is proportional to
the square of compliance rates, so that even with 75%
Table 1
Breast cancer prevention trials
Agent Intended
(versus placebo), duration of
Trial Population dose (mg/day) treatment (years)
RMH [5•] High risk Tamoxifen, 20 5–8
Family history
NSABP [3•] 1.6% 5-year risk Tamoxifen, 20 5
Italian [6•] Normal Risk Tamoxifen, 20 5
Hysterectomy
IBIS >Twofold risk Tamoxifen, 20 5
MORE [7•] Normal risk Raloxifene, 3
Osteoporotic 60 or 120
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compliance only about half of the potential efficacy informa-
tion is obtained. Compliance on tamoxifen was typically
approximately 5–10% less than that for placebo, which
reflects the dropout rate due to side effects.
Use of hormone replacement therapy
Many women entering the four tamoxifen chemoprevention
trials (IBIS, NSABP [3•], RMH [5•] and Italian [6•] studies)
were taking hormone replacement therapy (HRT). In all but
the NSABP study, they were able to continue HRT or
could start if menopausal symptoms became intolerable.
Thus, 14–26% of subjects had taken HRT in addition to
tamoxifen or placebo in the non-US trials. HRT use was
equally distributed between the two treatments in the RMH
and Italian studies, and has not been reported to date in
IBIS. Use of HRT was also proscribed in the MORE trial,
but 16% had used it previously. The potential confounding
effects of HRT in these studies is discussed below.
Breast cancer reduction
The early results of three tamoxifen studies have been
reported (NSABP [3•], RMH [5•] and Italian [6•] studies)
and are summarized in Table 2 and Figure 1. The IBIS trial
is due to recruit until the end of 2000, and will report 1 or
2 years later. The NSABP study showed a clear dramatic
reduction (odds ratio [OR] 0.51, 95% confidence interval
[CI] 0.39–0.66) in the incidence of invasive cancers in the
tamoxifen arm. This result is very similar to the reduction in
contralateral tumours reported in the overview of tamoxifen
adjuvant trials [4•]. The RMH and Italian trials did not show
appreciable treatment effects. In the RMH trial [5•] the
incidence curves for invasive cancers for the two arms are
superimposable. When the Italian trial [6•] was analyzed
according to whether subjects took medication for longer
than 1 year, there were indications of an effect (19 versus
11, OR 0.58), although the numbers are small and this
was an unplanned subgroup comparison. Also, there was
one case of breast cancer in the tamoxifen + HRT group,
compared with eight in the placebo + HRT group
(P=0.02), suggesting that tamoxifen is particularly effec-
tive in preventing cancers that are associated with exoge-
nous oestrogen use.
The MORE trial [7•] showed the greatest reduction in breast
cancer incidence (relative risk 0.35, 95% CI 0.21–0.58) on
the basis of 22 cancers in 5129 women assigned to ralox-
ifene (at 60 or 120mg) and of 32 cancers in 2576 women
assigned to placebo. The reduction in invasive breast
Table 2
Numbers of women randomized, follow-up periods and breast cancers detected (including in situ lesions)
Cancers
Median follow up Tamoxifen/
Trial Total randomized (months) Total raloxifene Placebo OR
RMH [5•] 2 471 70 70 34 36 0.94
NSABP [3•] 13 388 57 368 124 244 0.51
Italian [6•] 5 408 46 41 19 (11)† 22(19)‡ 0.91
IBIS* 6 037 30 88 –* –* –*
MORE [7•] 7 705 40 54 22/2‡ 32 0.35
*As of 1 December 1999 (ongoing and still blinded). †Tamoxifen >1 year. ‡2:1 ratio of raloxifene:placebo in MORE study.
Table 3
Demographic data from the five breast cancer prevention trials
Compliance (%)
First-degree Two or more
Age Age <50 relative with breast relatives with Tamoxifen/ HRT use on
Trial (median; years) years (%) cancer (%) breast cancer (%) raloxifene Placebo study (%)
RMH [5•] 4 76 2 9 6 4 2 7 48 62 6
NSABP [3•] 50–59 37 76 33 76 80 <10
Italian [6•] 51 38 12 ? 80 75 12
IBIS* 50 51 91 30 74 at 4 years 22
MORE [7•] 67 Very few 12† ? 78 at 3 years 75 10‡
*As of 1 December 1999 (accrual ongoing). †Defined as ‘family history of breast cancer’. ‡Raloxifene stopped when oestrogen started.tumours was even greater, giving an OR of 0.24 (95% CI
0.13–0.44) on the basis of 13 versus 27 cancers.
Very few patients have died in any of these trials, and even
for the NSABP study [3•] there was no direct evidence of
a reduction in breast cancer mortality (six patients on
placebo versus three patients on tamoxifen).
Oestrogen receptor-negative tumours
The incidence reduction in the NSABP study [3•] and
MORE trial [7•] is restricted to oestrogen receptor (ER)-
positive tumours. In the NSABP study the reduction was
67% for this group (OR 0.33, 95% CI 0.22–0.45),
whereas there was a slight increase in ER-negative
tumours (OR 1.22, 95% CI 0.74–2.03). Similarly in the
MORE trial ER-positive tumours were reduced by 90%
(OR 0.10, 95% CI 0.04–0.24), but there was little effect
on ER-negative tumours (OR 0.88, 95% CI 0.26–3.0).
Side effects
Endometrial cancer
Endometrial cancer is the most clearly recognized, if rare
side effect of tamoxifen. Several case reports and
case–control studies have found an effect [9], albeit of
highly variable size. The overview of adjuvant trials [4•]
found 92 endometrial cancers in users of tamoxifen, com-
pared with 32 cancers in control individuals, giving an OR
of 2.58 (95% CI 1.9–3.3). In the NSABP study [3•] the
excess was 36 cases versus 13, leading to a very similar
OR of 2.53 (95% CI 1.35–4.97). All of the cases identified
were International Federation of Gynecology and Obstet-
rics stage I, except one of the control patients who was
stage IV, and is the only patient reported to have died from
endometrial cancer. No increase in endometrial cancer was
found for women younger than 50 years, and the OR for
older women was 4.01. In the RMH study [5•] there were
four cases of endometrial cancer in the tamoxifen arm
versus one in the control individuals, and of course there
were none in the Italian study [6•] because all subjects had
had a hysterectomy. No data are available for the IBIS
study. In the MORE trial [7•] there was no effect on
endometrial cancer on the basis of six cases in the com-
bined raloxifene groups versus four in the control group.
Other cancers
No cancers other than endometrial were elevated in the
adjuvant overview [4•] or the NSAPB study [3•], and it
seems increasingly likely that tamoxifen has a minimal
effect on the development of other tumours, in contrast to
early concerns about liver and colorectal tumours [10–12].
Vascular events
Reports from women taking tamoxifen for breast cancer
suggested an increase in vascular events, but the relation
to tamoxifen by itself was in question because of the
potential confounding effect of chemotherapy and surgery.
The NSABP study [3•] clearly demonstrated that the
tamoxifen alone can increase the risk of these events, with
a 59% increase in strokes (1.45 versus 0.92 events per
1000 patient-years), a threefold increase in pulmonary
embolism (0.69 versus 0.23 cases per 1000 patient-
years) and a 60% increase in deep vein thrombosis (1.34
versus 0.84 cases per 1000 patient-years). Three of the
nine pulmonary embolisms in the tamoxifen group were
fatal. All of these excess risks were again confined to
women aged 50 years or older.
Similar results were reported in the Italian trial [6•], with 38
vascular events on tamoxifen and 18 on placebo
(P=0.005), although most of these were superficial
phlebitis and there were only nine were deep vein throm-
boses (six versus three, respectively) and two pulmonary
embolisms (one versus one, respectively).
Thromboembolic disease was also elevated with raloxifene
in the MORE trial [7•]. The magnitude was again about
threefold (OR 3.1, 95% CI 1.5–6.2) based on a rate of
3/1000 in the placebo arm and 9.5/1000 in the combined
raloxifene arms.
Menopausal symptoms
Both the RMH study and NSABP study have shown a
clear increase in menopausal symptoms (Table 4), the
most common of these was hot flushes, which rose from
17 to 33% in the RMH study [13] and from 65 to 78% in
the NSABP study [14]. Vaginal discharge and menstrual
http://breast-cancer-research.com/content/2/4/258
Figure 1
Forest plot of estimates of breast cancer incidence reduction for the
prevention trials. Summary estimate for tamoxifen trials is OR 0.58
(95% CI 0.48–0.71), and for all trials is OR 0.55 (95% CI 0.46–0.66),
both with P < 0.001. Heterogeneity tests give P = 0.07 for all
tamoxifen trials, including the NSABP Prevention 1 (P1) study in situ
strata, P = 0.04 without this strata, and P = 0.03 for all five strata. In
situ cancers are included in the totals, except for P1, for which they are
given separately. Data sources are as follows: P1 [3•], RHM study [5•],
Italian study [6•] and MORE [7•].
Odds ratio - log scale
.1 .5 1 1.5
Combined
MORE
Italian
RHM
P1 - DCIS
P1 - Invasive
All Tamoxifenirregularities were also more common in both trials. Less
specific factors such as weight gain, headaches, or
depression, which have been suggested as being related
to tamoxifen, were not elevated on tamoxifen in either trial.
Other negative effects
A few other effects, both positive and negative, appear to
be related in a small degree to tamoxifen exposure. The
NSABP study [14] has reported a 14% increase in
cataracts that was of marginal statistical significance, and
the RMH trial [15] has suggested a possible loss of bone
in premenopausal women.
Other beneficial effects
Bone
Several studies have shown that tamoxifen has beneficial
effects on bone tumour markers and bone mineral density
in postmenopausal women (for review, see [8]). It may
take some time for this to be fully translated into clinical
benefit because of the relatively young age of the women
in these trials. However, a nonsignificant 19% of fractures
at sites associated with osteoporosis (hip, Colles radius,
spine) has already been seen in the NSABP study [3•], but
no reduction in the much larger number of other fractures
was observed.
Raloxifene has been shown to improve bone biomarkers
[16], and recent data [17] show a reduction in vertebral
fractures.
Cardiovascular
There is little doubt that tamoxifen reduces low-density
lipoprotein cholesterol by about 20% (for review, see [8]).
The early reports of reductions in cardiovascular disease
in adjuvant trials [18,19] have yet to be confirmed in the
prevention trials, however. This again may relate to the
younger age distribution.
Discussion
The aim of this short review was to examine the available
results from the prevention trials and to attempt to explain
the difference in results between the NSABP study [3•]
and the European trials (IBIS and [5•–7•]) that have been
reported to date. At this stage there is more agreement on
side effects than on efficacy. The NSABP study is strongly
positive. The strength of these results is reflected in the P
value for the main effect (reduction in invasive tumours by
tamoxifen,  P<0.00001), and indicates the tiny chance
that the result arose by chance. Thus, given the size of the
effect, there can be little doubt that tamoxifen reduces the
incidence of breast cancer, and possible reasons for the
initial negative results from the European trials need to be
examined carefully.
No factor clearly explains these differences, and in terms
of entry criteria the RMH [5•] and Italian [6•] trials are more
different from each other than either are from the NSABP
study [3•]. The RMH trial recruited a high-risk population
with predominantly a strong family history, whereas the
Italian trial included a normal or even low-risk population
(because of the removal of the ovaries in many cases).
One factor that the European trials share but was not
allowed in the NSABP study [3•] (or the MORE trial [7•])
was concomitant HRT. Indirect observations suggest that
HRT use in both arms may tend to give a greater benefit
for tamoxifen, however. Because HRT is associated with
an increased risk of ER-positive breast cancer, more
endocrine-sensitive tumours might be expected in the
absence of tamoxifen and these are the tumours that
tamoxifen is particularly good at preventing. Indeed this
was found for the Italian trial, in which there were eight
cancers for HRT + placebo versus only one in the HRT +
tamoxifen group.
A test for heterogeneity between the trials is not signifi-
cant (P=0.07) if the NSABP study in situ lesions are
taken as a separate strata, and only marginally significant
(P=0.04) if they are excluded. Chance must still be con-
sidered as a serious explanation for the differences. The
results are all consistent with a 42% reduction in breast
cancer incidence, but the pooled estimate for the tamox-
ifen trials still has a 95% CI spanning anywhere from 30 to
55% reduction.
Conclusion
Perhaps the main conclusion is that there are no clear
conclusions at this stage. The RMH trial [5•] is relatively
Breast Cancer Research    Vol 2 No 4 Cuzick
Table 4
Common side-effects reported in two tamoxifen
chemoprevention trials
Tamoxifen Placebo
Side effect Trial (%) (%) P
Hot flushes RMH 34 20 <0.001
NSABP 78 65 <0.001
Vaginal discharge RMH 16 4 <0.001
NSABP 55 34 <0.001
Menstrual RMH 14 9 0.002
irregularities NSABP 22 21 NS
(bleeding)
Nausea RMH 6 10 0.02
Headaches RMH 12 14 NS
Mood change RMH 3 3 NS
NSABP 11 12 NS
Weight gain/loss RMH 7 11 NS
NSABP 45 42 NS
NS, not significant. Data for the RMH trial from [13]; Data for the
NSABP study from [3•,14].small and follow up in the Italian trial [6•] is relatively short.
The NSABP study [3•] results are biologically plausible
and in accord with the risk reduction seen in the contralat-
eral breast in the adjuvant tamoxifen trials [4•]. Overall, the
data support a breast cancer incidence reduction of about
40%, but the CI is wide. It is still unclear what effect this
will have on mortality, or indeed what the long-term effects
will be on incidence. Uncertainties exist as to which
women are most suitable for tamoxifen chemoprevention
(BRCA1/BRCA2 mutation carriers, weaker family histo-
ries, women with hormonal risk factors) and about the
potential interaction with HRT. It will be important to con-
tinue the follow up of the European trials. The IBIS trial will
be crucial in resolving the value of tamoxifen and, if posi-
tive, it will be important not to prematurely break the ran-
domization code in order to determine the long-term
benefits of tamoxifen prophylaxis.
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